期刊文献+

HPLC法测定阿加曲班原料药的含量及异构体比例 被引量:1

Determination of Argatroban and the Ratio of Isomer by HPLC
原文传递
导出
摘要 目的建立测定阿加曲班原料药含量及异构体比例的高效液相色谱(HPLC)法。方法采用Agilent ZORBAX SB-C18(100 mm×4.6 mm,1.8μm)色谱柱,以0.1%醋酸铵溶液(用冰醋酸调节p H值至5.5)-甲醇-乙腈(70∶15∶15,V/V)为流动相,检测波长为260 nm。结果阿加曲班的线性范围为159.7~372.6μg·m L^(-1)(r=1.000,n=5),定量限为0.3μg·m L^(-1)。结论本法简便准确,专属性强,分离度好,可用于测定阿加曲班原料药的含量及异构体比例。 OBJECTIVE To established an HPLC method for the determination of Argatroban and the ratio of isomer.METHODS The sample was separated on an Agilent ZORBAX SB-C18( 100 mm×4.6 mm,1.8 μm) with the mobile phase consisted of 0.1% ammonium acetate( adjusted with acetic acid to p H 5.5)-methanol-acetonitrile( 70 ∶15 ∶15,V/V). The detection wavelength was set at 260 nm. RESULTS There was a good linear relationship for Argatroban in the range of 159. 7-372. 6 μg·m L^(-1)( r = 1.000,n = 5).The limit of quantitation was 0.3 μg·m L^(-1). CONCLUSION The method is simple,accurate and has strong specialization for Argatroban and the ratio of isomer.
作者 陈静 林玲 CHEN Jing;LIN Ling(Guangzhou Institute for Drug Control,Guangzhou,Guangdong 510160,China)
出处 《今日药学》 CAS 2018年第8期526-527,541,共3页 Pharmacy Today
关键词 阿加曲班 异构体比例 含量测定 高效液相色谱法 Argatroban the ratio of isomer content determination HPLC
  • 相关文献

参考文献5

二级参考文献47

  • 1袁莉娟,刘爱民,刘蕾.新型凝血酶抑制剂阿加曲班[J].中国新药杂志,2005,14(2):230-234. 被引量:34
  • 2国家药典委员会.中国药典:二部[S].北京:中国医药科技出版社,2010:179-80.
  • 3张子彦,张宏卫.阿加曲班研究进展[J].国际内科学杂志,2007,34(8):483-485. 被引量:24
  • 4Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocy topenia and heparin-induced thrombocytopenia and thrombosis syndrome[J]. Semin Thromb Hemost, 1997,23(2): 197 - 202.
  • 5Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report [ J ]. Angiology, 1998,49 ( 1 ): 61 - 67.
  • 6Lewis BE,Grassman ED,Wrona L,et al. Novastan anticoagulation during renal stent implant in a patient with heparin-inducedthrombocytopenia[J ]. Blood Coagul Fibrinolysis, 1997,8 (1): 54 - 58.
  • 7Matsuo T, Yamada T, Yamanashi T, et al. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia[ J ]. Thromb Res, 1990,58 (6): 663 - 666.
  • 8Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis[ J ]. Thromb Res, 1988,52(10): 165 - 171.
  • 9Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia[J ]. Arch Intern Med ,2003,163(15): 1849 - 1856.
  • 10Cetta F, Graham LC, Wrona LL, et al. Argatroban use during pediatric interventional cardiac catheterization[J ]. Catheter Cardiovasc Interv, 2004,61 ( 1 ): 147 - 149.

共引文献38

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部